Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

Solid Biosciences (SLDB) Enterprise Value (2017 - 2024)

Solid Biosciences' Enterprise Value history spans 8 years, with the latest figure at -$171.1 million for Q3 2024.

  • For Q3 2024, Enterprise Value fell 19.76% year-over-year to -$171.1 million; the TTM value through Dec 2024 reached -$50.0 million, up 17.95%, while the annual FY2023 figure was -$49.6 million, 76.78% up from the prior year.
  • Enterprise Value for Q3 2024 was -$171.1 million at Solid Biosciences, up from -$190.3 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$400000.0 in Q1 2020 and bottomed at -$268.5 million in Q1 2021.
  • The 5-year median for Enterprise Value is -$167.0 million (2022), against an average of -$154.0 million.
  • The largest annual shift saw Enterprise Value skyrocketed 99.58% in 2020 before it crashed 67024.25% in 2021.
  • A 5-year view of Enterprise Value shows it stood at -$154.7 million in 2020, then tumbled by 34.27% to -$207.8 million in 2021, then decreased by 2.86% to -$213.7 million in 2022, then skyrocketed by 76.78% to -$49.6 million in 2023, then plummeted by 244.82% to -$171.1 million in 2024.
  • Per Business Quant, the three most recent readings for SLDB's Enterprise Value are -$171.1 million (Q3 2024), -$190.3 million (Q2 2024), and -$206.1 million (Q1 2024).